M&A for growth, 20 years of M&A in Italy, the best deals of 2023

Alfasigma shortlisted for M&A Awards for acquisition of Intercept Phamaceuticals in the USA

Alfasigma S.p.A has been selected as a finalist in the 20th edition of the M&A Awards: 20 Years of M&A in Italy, The Best Deals Of 2023, the initiative promoted by KPMG and Fineurop Soditic Spa, with the collaboration of Borsa Italiana and Class Editori, under the patronage of Bocconi University and AIFI, which rewards the best M&A transactions. The awards celebrate the importance of M&A as a strategic lever for business growth and competitiveness. Alfasigma has been shortlisted in the “Italian Acquisitions Abroad” category by a highly prestigious jury of industry experts, for the acquisition of Intercept Pharmaceuticals, Inc. 

The awards ceremony took place on Thursday 16 May at the headquarters of Borsa Italiana.

During the event, Francesco Balestrieri, CEO of Alfasigma, participated in a panel discussion: ‘M&A for Growth: Success Factors’ focusing on the evolution of M&A in the sector, and Alfasigma’s activity. Mr Balestrieri discussed the history of Alfasigma, one of Italy's leading pharmaceutical companies, born from the merger of two companies, Alfa Wassermann and Sigma-Tau, a company with established Italian roots that is embarking on a path of international growth with significant M&A transactions.

In the autumn of 2023, the company completed the acquisition of Nasdaq-listed biopharmaceutical company, Intercept Pharmaceuticals Inc. through a public takeover offer (IPO), strengthening its presence in the US and consolidating its market leadership in the gastrointestinal and rare liver disease area. With this acquisition, Alfasigma expanded its pipeline and strengthened its R&D activities with the addition of projects in various stages of development.



You’re entering Alfasigma global website

I agree